Introduction to GalNAc-ASO Technology GalNAc (N-acetylgalactosamine)-conjugated antisense oligonucleotides (ASOs) utilize triantennary GalNAc ligands to bind the asialoglycoprotein receptor (ASGPR) on hepatocytes. This enables receptor-mediated endocytosis, delivering ASOs specifically to liver […]
Introduction Toll-like receptors (TLRs) play a crucial role in innate immunity by detecting foreign RNA and triggering immune responses. Among these, TLR7 and TLR8 recognize RNA degradation products in endolysosomal compartments, […]
Oligonucleotide-based therapeutics represent a transformative approach in modern biomedicine, enabling targeted modulation of gene expression, splicing, protein interactions, and immune activation. From antisense oligonucleotides to siRNA, these therapies are redefining […]
A Breakthrough in Post-Transcriptional Regulation Key Takeaways Introduction In the intricate “micro-city” of the cell, messenger RNA (mRNA) molecules function like delivery parcels, carrying genetic instructions from DNA to ribosomes […]
Step-by-Step Guide for Research Applications The rapid expansion of mRNA technology from vaccine development to gene editing, protein replacement, and cellular reprogramming has created an urgent need for small-scale, high-quality […]
Nature Breakthrough: mRNA Vaccines Extend Poly(A) Tails, Boosting mRNA Stability and Immune Response
mRNA vaccines have played a pivotal role in curbing the COVID-19 pandemic. However, mRNA molecules are inherently unstable and prone to degradation—a feature that, while beneficial for safety, can limit […]
Introduction Splice-switching oligonucleotides (SSOs) are a class of antisense oligonucleotides (ASOs) designed to modulate pre-mRNA splicing by redirecting the splicing machinery to alter exon inclusion or exclusion [1]. By binding to […]
Principle of Deuterated Drugs Deuterium is an isotope of hydrogen, where its atomic nucleus contains one additional neutron compared to hydrogen, giving it an atomic mass that is twice that […]
Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy, and next-generation ADCs are redefining the landscape by overcoming the limitations of earlier designs. These advancements span all three core […]
Traditional ADCs: The Need for Precision Over the past decade, all FDA-approved antibody-drug conjugates (ADCs) have been heterogeneous mixtures composed of monoclonal antibodies (mAbs) conjugated with varying numbers of cytotoxic drugs […]